NR1H4 and metabolic dysfunction-associated steatohepatitis: Given the excellent therapeutic effects on metabolism, the FXR-ligand avermectins can provide a novel class of promising drugs to treat metabolic syndromes including NAFLD, NASH, hyperlipidemia, and diabetes.